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Background. The EGFR T790M mutation confers acquired resistance to kinase inhibitors in human EGFR mutant lung
adenocarcinoma, is occasionally detected before treatment, and may confer genetic susceptibility to lung cancer.
Methodology/Principal Findings. To study further its role in lung tumorigenesis, we developed mice with inducible
expression in type II pneumocytes of EGFR
T790M alone or together with a drug-sensitive L858R mutation. Both transgenic lines
develop lung adenocarcinomas that require mutant EGFR for tumor maintenance but are resistant to an EGFR kinase inhibitor.
EGFR
L858R+T790M-driven tumors are transiently targeted by hsp90 inhibition. Notably, EGFR
T790M-expressing animals develop
tumors with longer latency than EGFR
L858R+T790M-bearing mice and in the absence of additional kinase domain mutations.
Conclusions/Significance. These new mouse models of mutant EGFR-dependent lung adenocarcinomas provide insight into
clinical observations. The models should also be useful for developing improved therapies for patients with lung cancers
harboring EGFR
T790M alone or in conjunction with drug-sensitive EGFR kinase domain mutations.
Citation: Regales L, Balak MN, Gong Y, Politi K, Sawai A, et al (2007) Development of New Mouse Lung Tumor Models Expressing EGFR T790M
Mutants Associated with Clinical Resistance to Kinase Inhibitors. PLoS ONE 2(8): e810. doi:10.1371/journal.pone.0000810
INTRODUCTION
Point mutations in the kinase domain of mutant epidermal growth
factor receptors (EGFRs) are associated with acquired resistance to
the EGFR inhibitors, gefitinib (Iressa) and erlotinib (Tarceva) in
human lung adenocarcinoma [1–5]. The most common (.90%)
second-site mutation involves a CRT change at nucleotide 2369
in exon 20, which results in substitution of methionine for
threonine at position 790 (T790M). The amino acid change does
not appear to diminish the catalytic activity of EGFR, but based
upon crystal structure analyses, it is predicted to impair binding of
either gefitinib or erlotinib to the EGFR ATP-binding pocket [6].
Although identified in the context of drug resistance, emerging
data suggest that the T790M change may potentiate oncogenic
activity,eitherbyitselfor inassociation with alterationsintheEGFR
kinase domain already known to confer gain-of-function properties
[7–9]. Such alterations include deletions in exon 19 and point
mutations in exon 21 (L858R). For example, although somatic
T790M mutations in patients who never received gefitinib or
erlotinib are rare [2], they can occasionally be found in tumors with
primary drug resistance [10]. Second, rare cases of inherited
susceptibility to lung cancer may be associated with a germline
T790M mutation [11]. Third, we found the T790M mutation in an
EGFR
L858R-harboring lung adenocarcinoma cell line (H1975) that
was developed and propagated in vitro prior to the development of
EGFR kinase inhibitors [2]. Fourth, in a human bronchial epithelial
cell line, overexpression of EGFR
T790M confers a growth advantage
over cells expressing wildtype EGFR [12]. Finally, the analogous
substitution to T790M in BCR-ABL, T315I, is responsible for
acquired resistance to ABL inhibitors in chronic myelogenous
leukemia (CML) but has also been detected in CML patients before
treatment [13].
To study further the role of the EGFR
T790M mutant in lung
tumorigenesis in vivo, we have generated tetracycline (tet)-inducible
transgenicmicethatexpressinmouselungepitheliatheEGFR
T790M
mutant alone or in conjunction with a TKI-sensitive EGFR
L858R
mutant. We determined the effect of induction and de-induction of
the transgenes in these animals by the exogenous administration and
withdrawal, respectively, of the tet analog, doxycycline (dox). We
further tested whether T790M-expressing lung tumors would
respond to the kinase inhibitor, erlotinib, or an hsp90 inhibitor,
17-allylamino-17-demethoxygeldanamycin (17-AAG). The latter
drug has been previously shown to selectively degrade mutant
EGFR in cell culture and xenografts experiments [14,15].
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Generation of mice with tet-regulatable
EGFR
L858R+T790M transgenes
A tet-inducible system has been used to regulate the expression in
mouse lung epithelial cells of cDNAs encoding the commonly
encountered mutant EGFR alleles, EGFR
L858R and EGFR
del L747-
S752. Both mutants are associated with sensitivity to erlotinib [8,9].
Here, to facilitate comparisons, we used the same tet-inducible
system [9] to develop mouse lung tumor models that express the
EGFR
T790M mutant.
We first generated a double mutant EGFR allele encoding the
T790M mutation associated with EGFR kinase inhibitor resistance
together with the L858R mutation associated with drug sensitivity
(Figure 1). Transgene expression was induced in weaned double
transgenic progeny (harboring the CCSP-rtTA and tet-regulated
EGFR
L858R+T790M transgenes; ‘‘C/L858R+T790M’’) by adminis-
tering dox via the animal diet [16]. Mice were subsequently
screened at regular intervals via three ways: 1) for ‘‘clinical’’ signs
possibly indicative of lung cancer (e.g. tachypnea and cachexia), 2)
at the radiological level by magnetic resonance imaging (MRI) of
mouse lungs, and/or 3) after sacrifice, at the histopathological level
by analysis of lung sections. Among three founder lines identified
with abnormal lung pathology (numbers 12, 29, and 51), one line
(51) was particularly studied in further detail.
Inducible, lung-specific expression of the mutant
EGFR transgene in C/L858R+T790M mice
We observed that a bitransgenic mouse derived from line 51
became tachypneic and had an apparent large tumor burden on
MRI after being administered a dox-containing diet for
17.5 weeks (data not shown). A colony from this line was
subsequently expanded, and transgene-positive animals on dox
for varying amounts of time were sacrificed for further analyses.
To determine whether mutant EGFR expression was specific to
lung tissues from line 51 animals, we performed RT-PCR with
transgene specific primers on mRNA extracted from various
tissues derived from multiple progeny. Transgene expression was
detectable only in lung tissue (Figure 2A). Moreover, we could
not detect the transgene in control mice, i.e. in animals that
harbored only the CCSP-rtTA or EGFR
L858R+T790M transgenes
alone (Figure 2B).
Immunoblotting studies with an anti-EGFR
L858R-specific anti-
body [9] were next performed on extracts of lungs from various
non-, mono-, or bi-transgenic animals fed either a normal or dox-
containing diet. While mutant EGFR protein was detected in
lungs from C/L858R+T790M mice fed dox for 20 weeks, none
was detected in lungs from control animals (Figure 2C). Mutant
EGFR protein was also not detected in lung lysates from mice on
dox for 17 weeks (with documented radiographic lung lesions; see
below) and then subsequently fed a normal diet for 2 and 4 weeks,
respectively. Expression of the mutant protein correlated with the
detection of EGFR autophosphorylation at an important tyrosine
residue (Y1092) (Figure 2C). The timepoint at which induction
of EGFR
L858R+T790M protein can first be detected after initiation
of dox appears to be somewhat variable, because we were able to
detect the mutant protein after 2 weeks of induction in lungs from
some animals (data not shown) but not in others (Figure 2C).
RT-PCR performed on lung-derived mRNA showed similar
results regarding transcription of the transgene (data not shown).
Nevertheless, these results collectively indicate that we were able to
achieve inducible, lung-specific expression of mutant EGFR in C/
L858R+T790M mice.
C/L858R+T790M mice on dox develop lung
adenocarcinomas
We analyzed multiple untreated bitransgenic mice from line 51 fed
dox for varying amounts of time (0–32 weeks), to determine the
effect of mutant EGFR protein expression on mouse lungs
(Figure 3). Lungs from bitransgenic mice maintained without
dox exhibited normal lung morphology (Figure 3F). By contrast,
lungs from mice fed dox displayed heterogeneous adenocarcino-
mas (Figures 3A–D) involving three main histological subtypes:
solid (Figure 3A), bronchioloalveolar (Figures 3A, C), and
papillary (Figures 3B, D). Often, multiple histological subtypes
were observed in the same mouse in adjacent lesions (Figures 3A,
B). Immunohistochemical analyses revealed that tumors were
negative for CC26, a Clara cell protein (Figure 3G) and
positive for surfactant protein-C, a type II pneumocyte marker
(Figure 3H), indicating that the tumor cells had a type II cell-like
phenotype. Tumors were not examined for the presence of
bronchioalveolar stem cells, which display features of both type II
pneumocytes and Clara cells [17].
We previously used MRI to detect and monitor lung lesions in
other lung tumor models [9,18]. In EGFR
L858R+T790M animals,
lung lesions appeared mostly as dense solid consolidations
(Figures 4A and 5A). The patterns observed by MRI correlated
well with tumor histopathology (data not shown).
Expression of mutant EGFR is required for tumor
maintenance in C/L858R+T790M animals
To examine the dependence of EGFR
L858R+T790M-induced lung
tumors on continued expression of the mutant EGFR transgene,
we monitored lung lesions by MRI in six bitransgenic animals (on
dox for 13–32 weeks) after dox was removed. Serial MRIs showed
that lung tumors progressively regressed in all animals (Figure 4A
and data not shown). Regression was seen as early as one week
after removal of the inducer. By six weeks, MRI lesions appeared
to have mostly resolved (Figure 4A). The serial change over time
in lung opacities seen by MRI–presumably indicative of tumor
volume (cm
3) in an animal -- was readily quantifiable in individual
animals using imaging software (see methods and Figure 4B).
In animals sacrificed after dox withdrawal, lungs displayed
mostly degenerating tumors at the histological level (Figure 4C).
Consistent with this observation, immunoblotting of lung lysates
from the corresponding animals showed no detectable expression
of mutant EGFR (Figure 2C). However, microscopic islands of
tumor cells could still be detected on tissue sections, even after
mice were off dox for four weeks (Figure 4C, right panel).
Figure 1. Design of transgenic constructs. Tet–tetracycline; mp-1 pA–
poly A tract from the mouse protamine 1 gene; C–CCSP-rtTA.
Bitransgenic mice harboring both CCSP-rtTA and EGFR
L858R+T790M
transgenes were labeled ‘‘C/L858R+T790M’’. Bitransgenic mice harbor-
ing the EGFR
T790M and EGFR
L858R transgenes were labeled ‘‘C/T790M’’
and ‘‘C/L858R’’, respectively. The latter strain of mice were previously
described [9].
doi:10.1371/journal.pone.0000810.g001
EGFR
T790M Lung Tumor Models
PLoS ONE | www.plosone.org 2 August 2007 | Issue 8 | e810Lung tumors in C/L858R+T790M animals are
resistant to treatment with erlotinib
We next examined the effect of erlotinib on lung tumors in
C/L858R+T790M animals. Tumor-bearing animals with large
lung opacities on MRI were administered placebo (n=3) or
erlotinib (n=8) (Table S1 and Figure 5). The EGFR inhibitor
was given for 1 to 30 days at doses (25–50 mg/kg/d) known to be
effective at inducing regressions in C/L858R mice that bear drug-
sensitive tumors [9]. During the treatment period, many of the
animals became progressively dyspneic and had to be sacrificed at
timepoints earlier than originally planned. Among six evaluable
C/L858R+T790M animals assessed radiographically, none re-
sponded to erlotinib (Table S1 and Figure 5C).
The radiological data were further supported by subsequent
histological analyses of tumors from treated mice. While drug-
sensitive L858R-bearing lungs showed degenerating tumor after
erlotinib [9] (Figure 5B), EGFR
L858R+T790M-bearing tumors
contained virtually all viable cells with no treatment effect
(Figure 5B and Table S1). In addition, while the L858R-
bearing tumors displayed a greater than 10-fold decrease in
proliferation, the EGFR
L858R+T790M-bearing tumors did not
(Figure 5B and Figure S1). Furthermore, while L858R-treated
tumor cells demonstrated a dramatic decrease in phospho-EGFR
staining (Figure 5B), the treated C/L858R+T790M tumor cells
continued to display reactivity with phospho-EGFR antibody.
Consistent with this, immunoblotting analyses indicated that
lysates made from lungs of drug-treated C/L858R+T790M
animals continued to display reactivity with phospho-EGFR-
specific antibodies (Figure 5D). In total, none of the eight
erlotinib-treated animals displayed evidence of significant response
to the kinase inhibitor. When compared with drug-sensitive
C/L858R mice, where 12 of 12 mice displayed tumor responses at
doses $12.5 mg/kg/day [9], the difference in response rates
(100% vs 0%) was statistically significant (p,0.0001, Fisher’s
exact test).
To extend our findings to a separate line of C/L858R+T790M
animals, we treated a lung adenocarcinoma-bearing mouse (e.g.
Figure 3E) derived from a different founder (#12) with erlotinib
at 50 mg/kg/d for 12 days. Consistent with the results discussed
above, lung tumors in this animal did not show a response at either
the radiological or histological levels (data not shown).
Figure 2. Inducible, lung-specific expression of the mutant EGFR transgene in C/L858R+T790M mice (line 51). A, B. RT-PCR performed in the
presence or absence of reverse transcriptase (RT) using transgene-specific primers on mRNA from a bitransgenic animal on dox for 17.5 weeks (A)
and various mice (genotypes as indicated) on dox for 5.5 weeks (B). ‘‘+’’ and ‘‘2‘‘ denote known positive and negative lung samples derived from
bitransgenic and non-transgenic mice on dox, respectively. ‘‘C/L+T’’ denotes C/L858R+T790M animals. C. Immunoblotting with antibodies against
EGFR
L858R, EGFR Y1092, and actin was performed on lung lysates derived from various mice on and/or off dox for varying periods of time; W–weeks.
Genotypes are as indicated. ‘‘C/L+T’’ denotes C/L858R+T790M animals.
doi:10.1371/journal.pone.0000810.g002
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PLoS ONE | www.plosone.org 3 August 2007 | Issue 8 | e810Figure 3. C/L858R+T790M mice fed doxycycline develop lung adenocarcinomas. Hematoxylin and eosin (H&E)-stained sections (A–F) of lungs
derived from three different bitransgenic progeny of line 51 displaying different adenocarcinoma histological subtypes, including solid (A),
bronchioloalveolar (A, C), and papillary (B, D), and one of line 12 with solid and bronchioloalveolar subtypes (E), fed dox for 11 (A, C),1 6(D), 17.5 (B),
and 32 weeks (E), respectively. Lungs from bitransgenic mice fed a normal diet are shown in F. Lung tumors are composed mainly of type II
pneumocytes, as indicated by the lack of staining for the Clara cell marker, CC26 (G) and positive staining for the type II cell marker, surfactant
protein-C (SP-C) (H). Bars, 100 microns.
doi:10.1371/journal.pone.0000810.g003
Figure 4. Lung tumors in C/L858R+T790M mice require expression of mutant EGFR for tumor maintenance. A. Serial axial lung field MR images
from a mouse administered dox for 21 weeks (W) and then fed a normal diet for the indicated amounts of time. Arrows indicate lung opacities; H,
heart. B. Tumor volumes were quantified in the images depicted in A, using imaging software. See methods for details. C. H&E-stained sections from
lungs of bitransgenic mice on dox for 17 weeks with tumor by MRI and then taken off dox for the indicated times. Left–degenerating tumor
surrounding a scar; right–dying tumor cells surrounded by an inflammatory response; arrowed–island of viable tumor cells.
doi:10.1371/journal.pone.0000810.g004
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Using the same transgenic plasmid construct (Figure 1) and
bitransgenic system as described above, we also generated mice
expressing tetracycline-regulatable alleles carrying a mutant
EGFR
T790M cDNA alone. Thus far, we have identified 5 promising
founder lines (8, 22, 37, 45, and 71); lines 8 and 37 have been
characterized in most detail.
Bitransgenic progeny on dox were screened for lung tumors as
above. In most instances, animals from these lines developed
detectable lesions only after long-term administration of dox, and
we never observed the development of tachypnea or cachexia. In
mice derived from line 37, lung lesions were not visible by MRI
until about 28–32 weeks on dox (Figure 6A). These lesions
corresponded well with gross lung histology (Figure 6B). In line
8, while one animal was found to have visible lung lesions after
18 weeks on dox, another 5 animals developed lung lesions only
after 28–32 weeks. In lines 22, 45 and 71, lesions were detected
after 52, 40 and 32 weeks, respectively (data not shown).
Similar to C/L858R+T790M animals, C/T790M animals
(lines 37 and 8) displayed lung-specific expression of the mutant
Figure 5. Lung tumors in C/L858R+T790M mice are resistant to treatment with erlotinib. A. Serial axial (left) and coronal (right) images from C/
L858R or C/L858R+T790M mice, treated with erlotinib for 8 days. Arrow depicts tumor; H–heart. B. Histological sections derived from the lungs of C/
L858R (upper panel) or C/L858R+T790M (lower panel) mice treated with erlotinib for 0 or 8 days. Tumors were stained for the proliferation marker, Ki-
67, and phospho-EGFR (pEGFR, Y1016). Far right: H&E staining reveals significant treatment effect in a representative C/L858R tumor, but viable cells
in the corresponding C/L858R+T790M tumor. C. Tumor volumes were quantified in the MR images obtained from the individual mice pre- and post-
treatment with placebo or erlotinib. See Table S1 and methods for details. For comparison, tumor volumes from a drug-sensitive C/L858R mouse pre-
and post-erlotinib treatment and from a C/L858R+T790M mouse on and off dox for the indicated times are also displayed. W–weeks; D–days. D.
Immunoblotting with antibodies against EGFR
L858R, EGFR Y1092, and actin was performed on lysates derived from lungs of tumor-bearing C/
L858R+T790M mice, treated with placebo or erlotinib for the indicated times.
doi:10.1371/journal.pone.0000810.g005
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of lung sections revealed invasive lung adenocarcinomas with
a histological spectrum similar to those in C/L858R+T790M mice
(Figure 6D). Moreover, C/T790M tumors were dependent upon
mutant EGFR for survival, as tumors regressed after dox
withdrawal (Figures 6E and 6F). Finally, as expected, tumors
did not respond to erlotinib; none of five animals treated for 7 to
30 days with 50 mg/kg/d showed any tumor response (Table S2
and Figure 6G).
Others have reported that in a family with multiple cases of lung
adenocarcinoma associated with germline transmission of the
T790M mutation, four of six tumors analyzed by dideoxynucleo-
tide sequencing showed a secondary somatic activating EGFR
mutation, arising in cis with the germline T790M mutation [11].
To determine if tumors that arose in C/T790M animals similarly
had a secondary somatic activating EGFR mutation on the same
allele as the T790M mutation, we used oligonucleotide primers
that span the human EGFR kinase domain to perform transgene-
specific RT-PCR on mRNA derived from nine lung tumor
nodules derived from nine different animals (3 from line 37, 5 from
line 8, and 1 from line 22). Sequence analysis of the PCR products
revealed the presence of the T790M mutation, but no additional
kinase domain mutations were observed. Although we cannot
currently exclude the possibility of other cooperating oncogenes
that contribute to the lung tumors in these animals, these data
indicate that expression of EGFR
T790M alleles in mouse lung can
lead to lung tumor formation in vivo in the absence of more
common gain-of-function EGFR kinase domain mutations (i.e.
deletion mutations in exon 19 or the common L858R point
mutation in exon 21).
Interestingly, C/L858R+T790M (line 51) and C/T790M (line
8) animals on dox developed lung tumors with different latencies
Figure 6. Characteristics of C/T790M mice. A. Axial MR image from a line 37-derived bitransgenic animal fed dox for 32 weeks, revealing tumor (T);
H: heart. B. Gross histology shows corresponding lung lesions. C. RT-PCR was performed on lungs from this animal in the presence or absence of RT
using transgene-specific primers on mRNA from various tissues; ‘‘+’’–positive control; ‘‘2‘‘– negative control. D. Images of H&E-stained lung sections
from various T790M transgene bearing mice. Lungs from bitransgenic line 37 (i) and 8 animals (ii-iii) displayed features of papillary adenocarcinoma
(i), solid adenocarcinoma surrounded by bronchioloalveolar carcinoma (ii), and solid/papillary adenocarcinoma surrounded by bronchioloalveolar
carcinoma (iii). Tumors were negative for CC26 (iv), positive for SP-C (v), and positive for phospho-EGFR (Y1016) (vi). Bars, 100 microns. E. Serial MR
images of a bitransgenic C/T790M animal (line 8) administered dox 18 weeks (left) and then fed a normal diet for the indicated times; W–weeks.
F. H&E-stained sections from lungs of bitransgenic tumor-bearing mice withdrawn from dox for the indicated times. Left–degenerating tumor with
scattered viable cells; Right–hemosiderin-laden macrophages engulfing a degenerating tumor. G. Tumor volumes were quantitated in the MR images
obtained from the individual mice pre- and post-treatment with placebo or erlotinib. See Table S2 and methods for details. W–weeks, D–days.
doi:10.1371/journal.pone.0000810.g006
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the number of nodules per lung that developed in C/L858R+
T790M animals was greater than those observed in C/T790M
mice (Figure 7). These data are consistent with the notion that
the T790M mutation, when combined with activating EGFR
kinase domain mutations, confers enhanced catalytic phosphory-
lating activity, as shown by others using insect cells infected with
baculovirus expressing various EGFR intracellular domain con-
structs [19].
Antitumor activity induced by the hsp90 inhibitor,
17-AAG, in C/L858R+T790M mice
One goal of developing mouse tumor models that express
EGFR
T790M-driven lung adenocarcinomas is to use them to
identify agents that can potentially overcome T790M-mediated
resistance. Thus, as proof-of-principle, we treated tumor-bearing
C/L858R+T790M animals with the geldanamycin analogue,
17-AAG. This ansamycin antiobiotic acts by inhibiting hsp90,
a molecular chaperone which helps the folding of nascent
polypeptides and stabilizes oncogenic kinases [20]. It has been
shown in cell culture and xenograft models that 17-AAG can
degrade mutant EGFRs, including EGFR
L858R+T790M [14,15].
We first treated tumor-bearing C/L858R+T790M animals with
either placebo or 17-AAG, sacrificed mice 6 hours later, and
examined the levels of total EGFR in lung lysates. As compared to
extracts from lungs of mice treated with placebo, levels of EGFR
were lower in extracts from lungs of drug-treated mice
(Figure 8A), consistent with the notion that 17-AAG induces
degradation of EGFR. Degradation was accompanied by variable
effects on the phosphorylation of downstream components of the
EGFR signaling pathway (i.e. Erk and Akt) (Figure 8A). At the
histological level, lungs from 6h-treated animals displayed
evidence of treatment effect such as tumor necrosis (Figure 8B).
In contrast, lungs from placebo-treated animals displayed only
viable tumor (Figure 8B).
To assess the durability of 17-AAG-induced treatment,
additional animals were treated with 75 mg/kg/day of drug for
3 consecutive days per week for 1 week (n=6), 2 weeks (n=3), or
4 weeks (n=2). Control animals were treated with placebo for 3
consecutive days per week for 1 week (n=3) or 4 weeks (n=1).
This dosing schedule was previously shown to deliver the
maximum tolerated dose to mice [21]. Mice were assessed for
responses by MRI. Whereas 3 of 3 animals treated with placebo
displayed progressive disease, five of six animals treated with drug
for 3 days displayed partial responses (Table S3, Figure 8C and
Figure S2). Corresponding lung tumor tissue sections from
responding animals displayed tumor necrosis (Figure 8B).
However, in most treated animals, viable tumor nodules remained
(Figure 8B and data not shown). After 2 weeks of treatment, two
of three animals displayed partial responses, and after 4 weeks of
treatment, two of two animals displayed stable disease (Table S3,
Figure 8C and Figure S2). A transient antitumor effect was also
observed in tumor-bearing C/L858R mice (that express the
erlotinib-sensitive EGFR mutant) that were similarly treated with
17-AAG (data not shown). Collectively, these data indicate that the
hsp90 inhibitor, 17-AAG, has some antitumor effect against
T790M-driven lung tumors. However, the dosing schedule used
for these experiments induced only unsustained and modest
disease control.
DISCUSSION
Mutations that lead to substitution of methionine for threonine at
position 790 in the EGFR kinase domain have been found in
about 50% of tumors from patients with acquired resistance to the
EGFR inhibitors, gefitinib and erlotinib [1–5]. EGFR
T790M alleles
also have been detected in a minority of tumors with primary
resistance to these drugs [10]. Although such mutations are
predominantly somatic, a family with a germline T790M mutation
has also been described [11]. These human genetic data
underscore the significance of this particular mutation in human
lung cancer, especially in relation to targeted therapies.
In order to understand further the role of the EGFR
T790M
mutation in lung tumorigenesis, we have developed two new
inducible mouse models of lung cancer that express transgenes
encoding either EGFR
T790M or EGFR
L858R+T790M. The latter
construct encodes the T790M mutant in combination with the
drug-sensitive L858R mutant. Expression of either transgene
induces formation of heterogenous lung adenocarcinomas that
display histologies commonly found in human NSCLC, i.e. solid,
papillary, and bronchioloalveolar subtypes. Tumors from mice
expressing either allele are dependent upon mutant EGFR for
survival. Moreover, compared to mice that express the drug-
sensitive alleles, EGFR
L858R and EGFR
del L747-S752 [9], EGFR
T790M-
and EGFR
L858R+T790M-driven tumors are resistant to erlotinib.
Mice expressing the EGFR
T790M transgene alone usually
develop tumors with longer latency than animals expressing
EGFR
L858R+T790M (shown here) or even EGFR
L858R alone [9].
Importantly, tumor nodules from multiple C/T790M mice from
different founder lines do not appear to harbor secondary kinase
domain mutations arising in cis. These findings collectively
demonstrate that the mutant EGFR
T790M can induce lung tumor
formationinthe absenceof additionalgain-of-function EGFRkinase
domain mutations. However, because C/T790M mice develop
tumors with a relatively long latency, it is likely that other genes may
collaborate with EGFR
T790M to induce lung tumorigenesis.
How EGFR
T790M facilitates transformation remains to be fully
determined. Studies using global phosphoproteome analysis of
kinase inhibitor-resistant BCR-ABL mutants suggest that the
analogous T315I mutation in BCR-ABL substantially alters kinase
function and is associated with a unique phosphosubstrate signature,
such as a shift in phosphorylation of two tyrosines in the P-loop of
BCR-ABL [22]. It will be interesting in the future to determine if
EGFR
T790M similarly is associated with a unique phosphosubstrate
signature in EGFR. Such studies could provide insight into disease
progression as well as uncover new targets for therapy.
Finally, one aim of developing mouse tumor models that express
EGFR
T790M-driven lung adenocarcinomas is to use them to
identify agents that can potentially overcome T790M-mediated
Figure 7. Comparison of phenotypes induced by various EGFR
mutants. Representative pictures of H&E-stained lung sections from C/
T790M (line 8) and C/L858R+T790M (line 51) animals, fed dox for the
indicated amounts of time. W–weeks.
doi:10.1371/journal.pone.0000810.g007
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inhibitor, 17-AAG, which can target mutant EGFRs, at least in
cell culture or xenograft studies [14,15]. Our results demonstrate
that 17-AAG does have some modest antitumor activity against
EGFR
L858R+T790M-dependent tumors, as manifested by EGFR
degradation, in vivo radiographic responses, and histological
evidence for treatment effect. However, most tumor nodules in
mice remained viable, and any responses seen by MRI appeared
to be transient. Such results could be due to the short half-life of
17-AAG (6 hours) and an inability to dose the drug more
frequently due to hepatotoxicity [21]. However, these data are
consistent with xenograft model systems, where, compared to
placebo, 17-AAG treatment alone delayed but did not inhibit the
growth of xenografts comprised of H1975 cells (p value .0.05;
Sawai, Solit, and Rosen, unpublished). These cells harbor
EGFR
L858R+T790M and are resistant to gefitinib/erlotinib in vitro
[2]. In the future, we hope to find agents that can induce sustained
tumor responses in these lung tumor-bearing animals.
T790M-mediated resistance to EGFR inhibitors remains
a significant clinical problem. We have generated two new mouse
models that provide insights into clinical observations. The models
could help accelerate the development of improved therapies for
patients with lung cancers harboring EGFR
T790M alone or in
conjunction with drug-sensitive EGFR kinase domain mutations.
MATERIALS AND METHODS
Generation of transgenic mice
EGFR cDNAs encoding EGFR
T790M or EGFR
L858R+T790M [2] were
excised from pcDNA3.1(-) with PmeI and ligated into the tet-op-mp1
vector [18] via the EcoRV site, downstream of a tetracycline-
responsive element. To ensure stability of the mRNA, the 39 end
of the construct contains an intron and polyadenylation sequence
derived from the mouse protamine-1 gene. An extraneous 100 bp
SalI fragment, between the tet element and the ATG of EGFR,
was further excised from each construct as previously described
[9]. Entire DNA transgenes were released using BssHII and
injected into fertilized FVB F2 eggs by the MSKCC Transgenic
Core Facility. For the EGFR
L858R+T790M transgene, 60 pups were
obtained. For the EGFR
T790M transgene, two separate egg injec-
tions produced 212 pups. Tail PCR genotyping and/or Southern
blotting identified six and twenty-four founders, respectively, for
each transgene. Founders were subsequently crossed to mice that
express the reverse tetracycline transactivator (rtTA) in type II
pneumocytes (i.e. CCSP-rtTA) [23]. The latter animals were also
on an FVB background.
Animal husbandry and genotyping
All animals were housed in specific pathogen-free housing with
abundant food and water, and they were treated with various
drugs under guidelines approved by the MSKCC Institutional
Animal Care and Use Committee and Research Animal Resource
Center. CCSP-rtTA mice were previously described [23]. Doxycy-
cline was administered by feeding mice with dox-impregnanted
food pellets (625 ppm; Harlan-Teklad). TetO-EGFR transgenic
mice were genotyped using tail DNA, isolated with the Qiaprep
Tail DNeasy isolation kit (Qiagen), with the following primers:
EGFR3421, 59-ACTGTCCAGCCCACCTGTGT-39; and mp-
1R, 59-GCCTGCGACGGCGGCATCTGC-39. Reactions were
amplified with the following PCR protocol: denaturation for 5 min
at 95uC, followed by 35 cycles of 30 sec at 95uC, 30 sec at 58uC,
Figure 8. Effect of 17-AAG on lung tumors from C/L858R+T790M animals. A. Immunoblotting analyses of lung lysates derived from bitransgenic
animals (line 51) treated with placebo or 17-AAG and sacrificed 6 hours later. Lane numbers correspond with the animal study numbers in Table S3.
Lysates were probed with the indicated antibodies; p-phospho. B. Histology of lung tumors from bitransgenic mice treated with either placebo or
17-AAG for indicated times; H–hours; D–days. Lungs from placebo treated mice had viable tumor (upper panels), while lungs from drug-treated
animals displayed areas of tumor necrosis surrounded by rims of viable cells (two middle panels), and degenerating tumors with inflammatory
response (lower panels). Bars, 100 microns. C. Tumor volumes were quantitated in the MR images obtained from the individual mice pre- and post-
treatment with placebo or 17-AAG. See Table S3 and methods for details. D–days; W–weeks.
doi:10.1371/journal.pone.0000810.g008
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Transgenic founders were further confirmed by Southern blotting
of tail DNA, using a ,500 bp XhoI-SalI probe at the 59 end of the
construct.
Erlotinib (kindly provided by Genentech) was suspended in
0.5% (w/v) methylcellulose and injected intraperitoneally at the
doses and times indicated. 17-AAG (kindly provided by Conforma
Therapeutics, now Biogen Idec, Cambridge MA) was dissolved in
DMSO to yield 50mg/mL stock solutions and stored at 220uC.
The EPL diluent was obtained from the Drug Synthesis and
Chemistry Branch, Developmental Therapeutics Program, Na-
tional Cancer Institute. Prior to injection, 17-AAG was diluted
with EPL solution at a minimum of 1:3 and administered by i.p.
injection.
Histology
Animals were sacrificed with a lethal dose of CO2 per institutional
guidelines. In most instances after excision, the left lung was flash-
frozen in liquid nitrogen. The right lung was inflated with 4%
paraformaldehyde in PBS, fixed overnight at room temperature,
placed in 70% ethanol, and sent for paraffin embedding and
sectioning (Histoserv, Gaithersburg, MD). In some animals, gross
tumor nodules were macrodissected and flash-frozen, and the
remaining lung tissues were processed for histological analysis. All
lungs were sectioned in the same manner: 5 steps were taken, 100
microns apart. All steps were evaluated to determine whether
tumors were present. Slides were reviewed by a board-certified
pathologist with expertise in lung cancer (MFZ).
RT-PCR analysis
RNA was extracted from pulverized tissue samples using Trizol
(Invitrogen) reagent. RNA was treated with DNase I (Sigma) to
eliminate contaminating DNA. RT-PCR reactions were per-
formed using the SuperScript III One-Step RT-PCR with
Platinum Taq system (Invitrogen), with the following primers:
RT-PCR F: 59-ACCAAGCCACAGCAGGTCCT-39 and RT-
PCR R 59-TATGGTGTATGAGCGGCGGC-39. Control reac-
tions were performed with Platinum Taq polymerase in the
absence of reverse transcriptase.
Mutational analysis
To seek potential mutations in the coding sequence of the EGFR
kinase domain, RT-PCR analysis was performed as described
above on mRNA from discrete lung nodules macrodissected from
various mice. The following primers that span exons 18–21 were
used:2101F:59-CCCAACCAAGCTCTCTTGAG-39and2948R:
59-AATGACAAGGTAGCGCTGGGGG-39. PCR products were
then analyzed by direct dideoxynucleotide sequencing. All
sequence tracings were manually reviewed in the forward and
reverse directions.
Antibodies and immunoblotting
For experiments involving 17-AAG, tumor lysates were homog-
enized in SDS lysis buffer (50mM Tris-HCl (pH7.4) and 2% SDS).
For all other immunoblotting experiments, established protocols
were performed [24]. The following antibodies against specific
proteins were used: EGFR, phospho-EGFR (Y869, Y1016, 1092),
Akt, phospho-Akt, MAPK, phospho-MAPK (Cell Signaling,
Beverly, CA); and total EGFR (sc-03; Santa Cruz). The L858R-
antibody was previously described [9]. Note: two numbering
systems exist for EGFR. The first denotes the initiating methionine
in the signal sequence as amino acid -24. The second, used here,
denotes the methionine as amino acid +1.
MRI
Mice were imaged according to established protocolsby the MSKCC
Small Animal Imaging Core facility [9]. Briefly, animals were
anesthetized with 2% isoflurane oxygen gas. Two dimensional (axial
and coronal) MRI was then performed on a Bruker 4.7T Biospec
scanner (Bruker Biospin Inc.), using a custom-made 36mm quadra-
ture birdcage coil. ‘‘Tumor volume’’ (cm
3) per animal was quantified
by calculating the area of visible lung opacities present in each axial
image sequence (usually 20–22 per mouse), using ParaVision 3.0.2
imaging software, and then multiplying the total sum of the areas by
0.09 cm (the distance between each MRI sequence).
There are no standard response criteria for evaluating the effect
of drug treatment on lung tumors in mice. In humans, such criteria
are based on uni- or bidimensional measurements, obtained from
imaging studies where patients are conscious, placed in a certain
position, and asked to hold their breaths at specific times. In mice,
which are anesthesized, we have found that uni- or bi-dimensional
measurements are not as accurate to assess tumor responses (data
not shown). Therefore, we used tumor volume measurements and
the following criteria to classify tumor responses to treatment: 1)
complete response (CR): the disappearance of all target lesions; 2)
partial response (PR): at least a 30% decrease in the volume of
target lesions, taking as reference the baseline tumor volume; 3)
progressive disease (PD): at least a 20% increase in the volume of
target lesions, taking as reference the baseline tumor volume, and
4) stable disease (SD): neither sufficient shrinkage to qualify for
partial response nor sufficient increase to qualify for progressive
disease, taking as reference the baseline tumor volume.
SUPPORTING INFORMATION
Table S1 Summary of C/L858R+T790M bitransgenic mice
(line 51) treated with erlotinib.
Found at: doi:10.1371/journal.pone.0000810.s001 (0.06 MB
DOC)
Table S2 Summary of C/T790M bitransgenic mice treated with
erlotinib.
Found at: doi:10.1371/journal.pone.0000810.s002 (0.05 MB
DOC)
Table S3 Summary of C/L858R+T790M bitransgenic mice
(line 51) treated with 17-AAG.
Found at: doi:10.1371/journal.pone.0000810.s003 (0.09 MB
DOC)
Figure S1 Status of cell proliferation in lung tumors from
C/L858R and C/L858R+T790M animals treated with erlotinib.
Histological sections derived from the lungs of bitransgenic animals
were stained with antibodies to the proliferation marker, Ki-67. Ki-
67-positive cells in lungs were then quantitated by determining the
average (with standard deviations) number of positive cells counted
in three separate high power fields (hpf) at a magnification of 200x.
Found at: doi:10.1371/journal.pone.0000810.s004 (3.34 MB TIF)
Figure S2 Representative MR images from bitransgenic mice
treated with 17-AAG. Serial pre- and post-treatment images are
shown. D-days; W-weeks.
Found at: doi:10.1371/journal.pone.0000810.s005 (7.55 MB TIF)
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